Literature DB >> 22462746

CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.

Mark Y Chan1, Karen Tan, Huay-Cheem Tan, Pei-Tee Huan, Bei Li, Qian-Hui Phua, Hong-Kai Lee, Chi-Hang Lee, Adrian Low, Richard C Becker, Wen-Chong Ong, Mark A Richards, Agus Salim, E-Shyong Tai, Evelyn Koay.   

Abstract

UNLABELLED: AIM, MATERIALS &
METHODS: We investigated the functional significance of CYP2C19*2, *3, *17 and PON1 Q192R SNPs in 89 consecutive Asian patients on clopidogrel treatment and the prevalence of functionally significant polymorphisms among 300 Chinese, Malays and Asian Indians.
RESULTS: Both CYP2C19 loss-of-function alleles (*2 or *3) were associated with higher platelet reactivity while the CYP2C19 gain-of-function allele (*17) had lower platelet reactivity. For PON1, the median PRI was not significantly different between the QQ, QR and RR groups. The allele frequencies of CYP2C19*2, CYP2C19*3 and CYP2C19*17 were 0.280, 0.065 and 0.010 (rare) for Chinese, 0.310, 0.050 and 0.025 for Malays, and 0.375, 0.010 (rare) and 0.165 for Indians, respectively.
CONCLUSION: Our data suggest that genotyping studies to investigate clopidogrel response should include CYP2C19*2 and *3 but not *17 polymorphisms in Chinese, and CYP2C19*2 and *17 polymorphisms but not *3 in Indians. All three polymorphisms should preferably be genotyped in Malays.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22462746     DOI: 10.2217/pgs.12.24

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  10 in total

1.  Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome.

Authors:  Xu Liu; Yu Luo; Yan Lai; Yian Yao; Jimin Li; Yunkai Wang; S Lilly Zheng; Jianfeng Xu; Xuebo Liu
Journal:  J Genet       Date:  2016-06       Impact factor: 1.166

2.  Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12 inhibitor.

Authors:  Yifan Zhang; Xiaoxue Zhu; Yan Zhan; Xiaojiao Li; Cai Liu; Yunting Zhu; Hong Zhang; Haijing Wei; Yu Xia; Hongbin Sun; Yongqiang Liu; Xiaojuan Lai; Yanchun Gong; Xuefang Liu; Yongguo Li; Yanhua Ding; Dafang Zhong
Journal:  Br J Clin Pharmacol       Date:  2020-06-17       Impact factor: 4.335

3.  CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.

Authors:  Melissa Mejin; Wen Ni Tiong; Lana Yin Hui Lai; Lee Len Tiong; Adam Mohamad Bujang; Siaw San Hwang; Tiong Kiam Ong; Alan Yean Yip Fong
Journal:  Int J Clin Pharm       Date:  2013-05-10

4.  Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention.

Authors:  Yiding Li; Bee-Choo Tai; Winnie Sia; Qian-Hui Phua; Mark A Richards; Adrian Low; Koo-Hui Chan; Swee-Guan Teo; Tiong-Beng Sim; Chi-Hang Lee; Matthew T Roe; Tiong-Cheng Yeo; Huay-Cheem Tan; Mark Y Chan
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

5.  Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation.

Authors:  Liuh Ling Goh; Chia Wei Lim; Wey Cheng Sim; Li Xian Toh; Khai Pang Leong
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

6.  Development and validation of T-ARMS-PCR to detect CYP2C19*17 allele.

Authors:  Chenxi Jin; Zhikun Li; Xiaodi Zheng; Kailin Shen; Jiashuo Chao; Yifei Dong; Qin Huang; Qiulin Yin; Yan Deng; Weifeng Zhu
Journal:  J Clin Lab Anal       Date:  2019-08-22       Impact factor: 2.352

7.  Should CYP2C19 Genotyping Be Recommended as a Straight Forward Approach to Optimize Clopidogrel Utilization in Patients with Ischemic Stroke Complicated by Type 2 Diabetes Mellitus?

Authors:  Jialin Sun; Jing Li; Ping Leng; Chen Sun; Wen Xu; Zhenhuan Zhao; Xiao Li; Xiaolei Zhang
Journal:  Pharmgenomics Pers Med       Date:  2020-11-23

8.  CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease.

Authors:  Sudhir S Shetkar; Sivasubramanian Ramakrishnan; Sandeep Seth; Puneet Chandna; Sunil K Verma; Balram Bhargava; Vinay K Bahl
Journal:  Indian Heart J       Date:  2013-11-06

9.  Clopidogrel Pharmacokinetics in Malaysian Population Groups: The Impact of Inter-Ethnic Variability.

Authors:  Zaril H Zakaria; Alan Y Y Fong; Raj K S Badhan
Journal:  Pharmaceuticals (Basel)       Date:  2018-07-26

Review 10.  Drug-drug-gene interactions and adverse drug reactions.

Authors:  Mustafa Adnan Malki; Ewan Robert Pearson
Journal:  Pharmacogenomics J       Date:  2019-12-03       Impact factor: 3.550

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.